{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:47:34Z","timestamp":1773323254065,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T00:00:00Z","timestamp":1290556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The safety and efficacy of rituximab with CODOX\u2010M\/IVAC (cyclophosphamide, doxorubicin, vincristine, methotrexate\/ifosfamide, etoposide, high dose cytarabine) was retrospectively analysed in 23 patients with non\u2010human immunodeficiency virus\u2010related B\u2010cell non\u2010Hodgkin lymphoma with proliferation index &gt;95% [14 with classical Burkitt lymphoma (BL), five with B\u2010cell lymphoma unclassifiable, with features intermediate between diffuse large B cell lymphoma (DLBCL) and BL, and four with DLBCL]. Six (26%) low\u2010risk (LR) patients received three cycles of CODOX\u2010M and 17 (74%) high\u2010risk (HR) cases were assigned to four cycles of alternating CODOX\u2010M\/IVAC. Rituximab 375\u2003mg\/m<jats:sup>2<\/jats:sup> was infused on days 1 and 10 of each cycle. Toxicity was comparable to that reported with CODOX\u2010M\/IVAC, with no treatment\u2010related death. Two patients developed grade 3 rituximab\u2010induced delayed neutropenia, with no adverse outcome. After completing treatment, 83% LR patients and 71% HR patients achieved CR by positron emission tomography\u2013computerized tomography (PET\u2013CT). Three (13%) patients received salvage treatment. At a median follow\u2010up of 34\u2003months (range\u2003= 18\u201375), 19 (83%) patients (100% LR and 74% HR) were alive, including one case undergoing salvage for late relapse. Four HR patients (17%) had died, three from primary progressive disease and one from treatment\u2010refractory relapse 2\u2003months after achieving CR. These results with R\u2010CODOX\u2010M\/R\u2010IVAC compare favourably with existing data using CODOX\u2010M\/IVAC and warrant further prospective studies. The potential pitfalls of PET\u2013CT to assess response are highlighted.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08447.x","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T10:23:59Z","timestamp":1290594239000},"page":"175-181","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Rituximab in combination with CODOX\u2010M\/IVAC: a retrospective analysis of 23 cases of non\u2010HIV related B\u2010cell non\u2010Hodgkin lymphoma with proliferation index &gt;95%"],"prefix":"10.1111","volume":"152","author":[{"given":"Sajir G.","family":"Mohamedbhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Sibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Marafioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony H.","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Linch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_6_4_1","first-page":"8035","article-title":"Efficacy and toxicity of dose\u2010adjusted EPOCH\u2010rituximab in adults with newly diagnosed Burkitt lymphoma","volume":"25","author":"Dunleavy K.","year":"2007","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Proceedings Part I)"},{"key":"e_1_2_6_5_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177469"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2009.07.035"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3282f5123d"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.925"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf253"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145128"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_6_14_1","volume-title":"WHO Classification of Tumours of Haematological and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_6_16_1","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment","author":"WHO","year":"1979"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0758-2"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08447.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08447.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:44:24Z","timestamp":1697406264000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08447.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,24]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08447.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08447.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,24]]},"assertion":[{"value":"2010-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}